Zalicus Inc., a biopharmaceutical company, engages in the development of drug candidates focusing on the treatment of pain and inflammation. The company's clinical and preclinical product candidates for pain, inflammation, and other central nervous system disorders include Synavive (CRx-102), a novel dissociated glucocorticoid product candidate, which has completed Phase II clinical trials in subjects with knee osteoarthritis, to treat immuno-inflammatory disorders; Prednisporin (FOV1101), a topical ophthalmic drug candidate containing low doses of the glucocorticoid prednisolone acetate and the immunosuppressant cyclosporine A; N-type and T-type calcium channel blockers for the treatment of chronic pain; and CRx-601, a formulation of carbidopa and levodopa for the treatment of Parkinson's disease. It is also developing CRx-401 for Type 2 diabetes; CRx-191 and CRx-197 for psoriasis. It has a research collaboration and license agreement with the Novartis Institutes of Biomedical Research; a collaboration agreement with PGxHealth, LLC for the development of ATL313, an adenosine A2A receptor agonist compound owned by PGxHealth; collaboration agreement with Mallinckrodt Inc., Fovea Pharmaceuticals SA, and National Institutes of Allergy and Infectious Diseases; and a cooperative research and development agreement with the United States Army Medical Research Institute for Infectious Diseases. The company was formerly known as CombinatoRx, Incorporated and changed its name to Zalicus Inc. on September 9, 2010. Zalicus Inc. was founded in 2000 and is based in Cambridge, Massachusetts.